Trial Profile

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Personalised cancer therapy-BriaCell Therapeutics (Primary) ; Tislelizumab (Primary) ; Cyclophosphamide; Peginterferon alfa-2a
Indications Advanced breast cancer; Cancer metastases; HER2 negative breast cancer
Focus Adverse reactions; First in man; Proof of concept
Acronyms Bria-OTS
Sponsors BriaCell Therapeutics Corp

Most Recent Events

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
22 May 2026 According to BriaCell Therapeutics Corp media release, data from this study will be presented at the 2026 ASCO Annual Meeting, taking place May 29-June 2, 2026 at McCormick Place, Chicago, Illinois.
22 May 2026 Results presented in a BriaCell Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com